Xueyan Yang

570 total citations · 1 hit paper
18 papers, 380 citations indexed

About

Xueyan Yang is a scholar working on Molecular Biology, Nephrology and Epidemiology. According to data from OpenAlex, Xueyan Yang has authored 18 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Nephrology and 6 papers in Epidemiology. Recurrent topics in Xueyan Yang's work include Acute Kidney Injury Research (5 papers), Liver Disease Diagnosis and Treatment (3 papers) and Chronic Kidney Disease and Diabetes (3 papers). Xueyan Yang is often cited by papers focused on Acute Kidney Injury Research (5 papers), Liver Disease Diagnosis and Treatment (3 papers) and Chronic Kidney Disease and Diabetes (3 papers). Xueyan Yang collaborates with scholars based in China and United States. Xueyan Yang's co-authors include Jijia Hu, Jun Feng, Zhaowei Chen, Zijing Zhu, Dingping Yang, Guohua Ding, Wei Liang, Jie Song, Xiaojie Yan and Hongyan Liu and has published in prestigious journals such as The Journal of Infectious Diseases, Cellular and Molecular Life Sciences and Molecules.

In The Last Decade

Xueyan Yang

15 papers receiving 377 citations

Hit Papers

Transition of acute kidne... 2022 2026 2023 2024 2022 25 50 75 100

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xueyan Yang China 10 169 131 71 41 40 18 380
Weiyan Lai China 9 139 0.8× 113 0.9× 79 1.1× 32 0.8× 64 1.6× 15 389
Changying Xing China 8 147 0.9× 132 1.0× 67 0.9× 31 0.8× 14 0.3× 18 340
Mark A. Bryniarski United States 10 188 1.1× 76 0.6× 50 0.7× 66 1.6× 59 1.5× 14 411
Nan Mao China 11 128 0.8× 78 0.6× 67 0.9× 10 0.2× 13 0.3× 33 289
You Na China 6 175 1.0× 50 0.4× 130 1.8× 37 0.9× 66 1.6× 8 364
Suyan Duan China 12 204 1.2× 209 1.6× 114 1.6× 65 1.6× 10 0.3× 38 527
Bing Du China 13 150 0.9× 49 0.4× 136 1.9× 32 0.8× 12 0.3× 29 504
Huimin Xian China 4 270 1.6× 41 0.3× 116 1.6× 25 0.6× 14 0.3× 7 448
Adeel Ijaz United States 5 149 0.9× 188 1.4× 37 0.5× 59 1.4× 5 0.1× 8 459
Jiawei Tang China 11 108 0.6× 115 0.9× 20 0.3× 9 0.2× 16 0.4× 19 342

Countries citing papers authored by Xueyan Yang

Since Specialization
Citations

This map shows the geographic impact of Xueyan Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xueyan Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xueyan Yang more than expected).

Fields of papers citing papers by Xueyan Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xueyan Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xueyan Yang. The network helps show where Xueyan Yang may publish in the future.

Co-authorship network of co-authors of Xueyan Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Xueyan Yang. A scholar is included among the top collaborators of Xueyan Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xueyan Yang. Xueyan Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Yang, Xueyan, Yu‐Xin Tian, Xidong Li, et al.. (2025). Performance of the AASLD, EASL, and APASL Clinical Practice Guidelines in"grey zone"stages of Chinese patients with chronic hepatitis B. Hepatology International. 19(4). 796–808.
2.
Yang, Xueyan, Xidong Li, Qiao Yang, et al.. (2025). A Model to Identify Gray Zone Patients With Chronic Hepatitis B Requiring Antiviral Therapy: A Multicenter Retrospective Study. The Journal of Infectious Diseases. 232(2). 485–498.
3.
Chen, Xinghua, Zijing Zhu, Yiqun Hao, et al.. (2024). STING contributes to lipopolysaccharide-induced tubular cell inflammation and pyroptosis by activating endoplasmic reticulum stress in acute kidney injury. Cell Death and Disease. 15(3). 217–217. 42 indexed citations
4.
Gao, Wenxia, Chunxue Zhang, Xueyan Yang, et al.. (2024). Can miRNAs in MSCs-EVs Offer a Potential Treatment for Hypoxic-ischemic Encephalopathy?. Stem Cell Reviews and Reports. 21(1). 236–253. 5 indexed citations
5.
Yang, Xueyan, Yu‐Xin Tian, Feng Jin, et al.. (2024). Dose-dependent Relationship between Alcohol Consumption and the Risks of Hepatitis B Virus-associated Cirrhosis and Hepatocellular Carcinoma: A Meta-analysis and Systematic Review. Journal of Clinical and Translational Hepatology. 0(0). 0–0. 2 indexed citations
7.
Yang, Xueyan, et al.. (2023). Ox‐LDL aggravates contrast‐induced injury of renal tubular epithelial cells. Journal of Biochemical and Molecular Toxicology. 37(8). e23379–e23379. 5 indexed citations
8.
Chen, Zhaowei, Zijing Zhu, Yiqun Hao, et al.. (2022). Angiotensin II induces podocyte metabolic reprogramming from glycolysis to glycerol-3-phosphate biosynthesis. Cellular Signalling. 99. 110443–110443. 6 indexed citations
9.
Zhu, Zijing, Jijia Hu, Zhaowei Chen, et al.. (2022). Transition of acute kidney injury to chronic kidney disease: role of metabolic reprogramming. Metabolism. 131. 155194–155194. 108 indexed citations breakdown →
10.
Yang, Xueyan, et al.. (2022). SIRT3 deficiency exacerbates early-stage fibrosis after ischaemia-reperfusion-induced AKI. Cellular Signalling. 93. 110284–110284. 28 indexed citations
11.
Yang, Yifei, Xueyan Yang, Hongyan Liu, et al.. (2022). Sirt3 mitigates LPS‐induced mitochondrial damage in renal tubular epithelial cells by deacetylating YME1L1. Cell Proliferation. 56(2). e13362–e13362. 36 indexed citations
12.
Yang, Xueyan, Jun Feng, Wei Liang, et al.. (2021). Roles of SIRT6 in kidney disease: a novel therapeutic target. Cellular and Molecular Life Sciences. 79(1). 53–53. 33 indexed citations
13.
Huang, Shuo, Yanyan Tang, Tianjun Liu, et al.. (2020). A Novel Antioxidant Protects Against Contrast Medium-Induced Acute Kidney Injury in Rats. Frontiers in Pharmacology. 11. 599577–599577. 16 indexed citations
15.
Yang, Xueyan, Yifan Zhang, Lijia Liu, et al.. (2017). Lignans and diterpenes isolated from Tirpitzia ovoidea and their biological activities. Chinese Journal of Natural Medicines. 15(12). 938–943. 4 indexed citations
16.
Wang, Qinghui, et al.. (2017). Flavonoids isolated from Sinopodophylli Fructus and their bioactivities against human breast cancer cells. Chinese Journal of Natural Medicines. 15(3). 225–233. 13 indexed citations
17.
Yang, Xueyan, Lan Yu, Meili Lü, et al.. (2016). Simvastatin inhibited oxLDL-induced proatherogenic effects through calpain-1–PPARγ–CD36 pathway. Canadian Journal of Physiology and Pharmacology. 94(12). 1336–1343. 22 indexed citations
18.
Su, Dan, Xueyan Yang, Feng Xu, Ming‐Ying Shang, & Shao‐Qing Cai. (2014). The Diterpenes Ovoideal A–G from Tirpitzia ovoidea. Molecules. 19(11). 18966–18979. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026